Abstract: This invention relates to novel 15O-labeled monosaccharide useful for positron emission tomography (PET) and producing method thereof.

Abstract: A method of highly efficiently transferring various selected molecules into various cells and a method of fusing cells. Cells and/or selected molecules such as polynucleotide are treated with cold gas plasma to thereby transfer the selected molecules located around cells into the cells, or cells are fused by treating the cells with cold gas plasma. Moreover, an apparatus for transferring selected molecules or fusing cells having a cold gas plasma generation unit for transferring selected molecules into cells is provided.

Abstract: The present invention identified OVARC1000473 (SEQ ID NO: 1) and NT2RM1000377 (SEQ ID NO: 3) as clones showing suppression of CREB activation by forskolin, and provides evaluation methods using these genes, and/or proteins encoded by these genes. Furthermore, these proteins were found to enhance cell damage. Compounds that can be screened based on the evaluation methods of this invention are useful as agents for inhibiting the CREB dephosphorylation reaction, agents for suppressing enhancement of cell damage, and preventive and therapeutic agents for memory disorders and/or neurodegenerative disorders.

Abstract: This invention relates to novel 15O-labeled monosaccharide useful for positron emission tomography (PET) and producing method thereof.

Abstract: It is intended to provide a contrast medium for thrombus capable of binding specifically to a thrombus, lowering background noise and thus improving the resolution in a contrast examination for thrombus formation; and a method of detecting a thrombus by using the same. A contrast medium for thrombus comprising, as the active substance, a substance obtained by labeling a compound capable of binding to GPIIb/IIIa which is selected from among compounds represented by the general formulae (I) to (IV) and physiologically acceptable salts thereof, and a method of detecting a thrombus by using the same.

Abstract: The present invention relates to novel nuclear receptor ERR?3. Although ERR?3 itself lacks a DNA binding domain, it comprises the function of enhancing the transcriptional activation function of arbitrary nuclear receptors, such as ERR, ER, or TR. Moreover, the present inventors found that, like ERR?3, the known proteins ERR?1 and ERR?2 also comprise the function of enhancing the transcriptional activation function of other nuclear receptors. Thus, the present invention provides methods for evaluating the regulatory function of these ERR? subtypes in enhancing the transcriptional activation function of other nuclear receptors, and screening methods based on these evaluation methods.

Abstract: The present invention identified OVARC1000473 (SEQ ID NO: 1) and NT2RM1000377 (SEQ ID NO: 3) as clones showing suppression of CREB activation by forskolin, and provides evaluation methods using these genes, and/or proteins encoded by these genes. Furthermore, these proteins were found to enhance cell damage. Compounds that can be screened based on the evaluation methods of this invention are useful as agents for inhibiting the CREB dephosphorylation reaction, agents for suppressing enhancement of cell damage, and preventive and therapeutic agents for memory disorders and/or neurodegenerative disorders.

Abstract: The present invention relates to the novel isoforms, RXR?2 and RXR?3, of nuclear receptor RXR?. Unlike known isoform RXR?1, the transcriptional activation functions of RXR?2 and RXR?3 are augmented by SRC-1. The present invention provides methods for evaluating the function of regulating augmentation by co-activators of these RXR? isoforms, and screening methods based on these evaluation methods. By controlling the interaction between isoforms and co-activators, transcription-controlling activity can be regulated in an isoform-specific manner.

Abstract: A method of highly efficiently transferring various selected molecules into various cells and a method of fusing cells. Cells and/or selected molecules such as polynucleotide are treated with cold gas plasma to thereby transfer the selected molecules located around cells into the cells, or cells are fused by treating the cells with cold gas plasma. Moreover, an apparatus for transferring selected molecules or fusing cells having a cold gas plasma generation unit for transferring selected molecules into cells is provided.

Abstract: Primaiy supernatant liquid collector 1 allows blood A to separate into a primary supernatant liquid B and red blood cells by leaving the blood A stationary for a prescribed period of time, and then it discharges the primary supernatant liquid B and physiological saline W in the same amount into a first treatment container 13 and a first balance container 14, respectively. Centrifuge 61 centrifuges the above primary supernatant liquid B using the first balance container 14 as a balance weight, and a secondary supernatant liquid in the first treatment container 13 is transferred to a second treatment container 109 by take-out device 91 and at the same time the physiological saline W in the same amount as the transferred secondary supernatant liquid is transferred from the first balance container 14 to a second balance container 110.

Abstract: Primary supernatant liquid collecting means 1 allows blood A to separate into a primary supernatant liquid B and red blood cells by leaving the blood A stationary for a prescribed period of time, and then it discharges the primary supernatant liquid B and physiological saline W in the same amount into a first treatment container 13 and a first balance container 14, respectively.

Abstract: The present invention relates to a novel pyrazolopyridine compound of the following formula: wherein R1 is aryl, and R2 is cyclo(lower)alkyl which may have one or more suitable substituent(s), etc; and a pharmaceutically acceptable salt thereof, which is useful as a medicament; the processes for the preparation of said pyrazolopyridine compound or a salt thereof; a pharmaceutical composition comprising said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof; etc.

Abstract: The present invention relates to a novel pyrazolopyridine compound of the following formula: ##STR1## wherein R.sup.1 is aryl, andR.sup.2 is cyclo(lower)alkyl which may have one or more suitable substituent(s), etc; and a pharmaceutically acceptable salt thereof, which is useful as a medicament; the processes for the preparation of said pyrazolopyridine compound or a salt thereof; a pharmaceutical composition comprising said pyrazolopyridine compound or a pharmaceutically acceptable salt thereof; etc.

Abstract: A water-soluble antibiotic composition which comprises crystals of a cephem compound of the following formula: ##STR1## wherein R.sup.1 is a residue of an aliphatic hydrocarbon which may have suitable substituent(s), andR.sup.2 is a heteronio (lower)alkyl, or an acid addition salt thereof, and a pharmaceutically acceptable carbonic acid salt.And a salt of new cephem compound derived from the above-mentioned cephem compound.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl, lower alkanoyl, aryl, ar(lower)alkyl or a heterocyclic group, each of which may have suitable substituent(s),R.sup.2 is carboxy or protected carboxy,R.sup.3 is hydrogen, halogen, hydroxy, lower alkoxy, acyloxy, lower alkylthio, lower alkenyl, lower alkenylthio, lower alkynyl, heterocycliothio or a heterocyclic group, in which lower alkylthio, lower alkenyl, lower alkenylthio, heterocyclicthio and a heterocyclic group may have suitable substituent(s),R.sup.4 and R.sup.5 are each hydrogen, halogen or arylthio,A is lower alkylene, andn is an integer of 0 or 1,and a pharmaceutically acceptable salt thereof, processes for preparation thereof and pharmaceutical composition comprising the same.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl, lower alkanoyl, aryl, ar(lower)alkyl or a heterocyclic group, each of which may have suitable substituent(s),R.sup.2 is carboxy or protected carboxy,R.sup.3 is hydrogen, halogen, hydroxy, lower alkoxy, acyloxy, lower alkylthio, lower alkenyl, lower alkenylthio, lower alkynyl, heterocyclicthio or a heterocyclic group, in which lower alkylthio, lower alkenyl, lower alkenylthio, heterocyclicthio and a heterocyclic group may have suitable substituent(s),R.sup.4 and R.sup.5 are each hydrogen, halogen or arylthio,A is lower alkylene, andn is an integer of 0 or 1,and a pharmaceutically acceptable salt thereof, processes for preparation thereof and pharmaceutical composition comprising the same.